October 16, 2024 06:30 AM EDT
Deals
R&D

Take­da parts ways with Wave Life Sci­ences even with Hunt­ing­ton’s tri­al win

Ayisha Sharma

News Reporter

Take­da will not move for­ward with Wave Life Sci­ences on a Hunt­ing­ton’s dis­ease drug, end­ing their col­lab­o­ra­tion that first start­ed in 2018 with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times